NOVORAPID PENFILL (NovoRapid Penfill)

     Synonym : Insulin aspart, Insulin aspart

     The composition and the form of : 1 ml injection of insulin biosinteticheskogo asparta ED 100; In Penfill 3 ml cartridges (for use with insulin pumps handle NovoPen 3, NovoPen 3 Demi, Innovo and needles NovoFayn); In the blister package 5 cartridges.

     Description : Insulin aspart-short-acting insulin analogue, obtained by biotechnology, in which the amino acid proline at position B28 filled at asparaginovuyu acid.

     The drugs act : Gipoglikemicheskoe.

The mechanism of the hypoglycemic insulin aspart is that the molecules to absorb glucose, making contact with the receptor for insulin in muscle and fat cells, while inhibiting production of glucose biscuits.

     Pharmacokinetics : proline amino acid substitution at position B28 in asparaginovuyu acid reduces the tendency of molecules to education geksamerov that occurs with conventional insulin solution, so much faster drug absorbed from the subcutaneous fat than the solution of human insulin. Time to Cmax, on average, two times less than the solution of human insulin. Cmax is 40 minutes, returning to the starting-by 4-6 h.

     Farmakodinamika : NovoRapid Penfill starts much faster than human insulin solution, and stronger lowers glucose levels in the first 4 h after a meal. Duration of the following S / to the introduction of shorter than the solution of human insulin. Effect develops through 10-20 minutes after the S / introduction to the area in the abdominal wall, reaches its maximum after 1-3 hours and lasts 3-5 hours

     Indication : Diabetes mellitus.

     Contraindications : Giperchuvstvitelnost, hypoglycaemia.

     Application of pregnancy and breastfeeding : Clinical Experience of application NovoRapid Penfill pregnancy is limited. Restrictions on the use of insulin aspart nursing mothers not, but it may be necessary to correct dose.

     Side Effects : Gipoglikemiya sometimes transient swelling, and violations of refraction, local allergic reaction (redness, swelling and itching at the injection); In rare cases, Generalized hypersensitivity reaction (potentially life-threatening); Perhaps lipodistrofii development at the injection (if the patient long-term no change of injections).

     Networking : MAO inhibitors, beta-selective adrenoblokatory, ACE inhibitors, musk, anabolic steroids, oral gipoglikemicheskie funds oktreotid, sulfanilamidy, alcohol can reduce the need for insulin, oral contraceptives, corticosteroids, Thyroid hormones, and simpatomimetiki danazol-increasing need for insulin .

     Overdosing : Symptoms : development of hypoglycemia (cold sweat, rapid heartbeat, tremor, a sense of hunger, excitement, irritability, paleness, headache, drowsiness, lack of movement, speech and violation of depression). Severe hypoglycemia can cause coma and brain functions.

Treatment : sugar, or glucose inside (if the patient in mind), S / to, in / m-Glucagon (0,5-1 mg dose) or / in-glucose. In addition, the / in a glucose needed when in 10-15 minutes after the patient glyukagona not awakes. After the restoration of consciousness recommended oral carbohydrates to prevent relapse hypoglycemia.

     Dosing and Administration : P / to the area in the abdominal wall, hip, shoulder or butt, just before receiving food (prandialno) or immediately after eating (postprandialno). Places injection in the same section of the body must be regularly changed. Dose regime and the introduction determine individually, because drug absorbed quickly and Cmax in patients of different age groups vary. Usually NovoRapid Penfill used in combination with insulin therapy medium and long-term actions (basal insulin). Individual demand for insulin is usually between 0.5 to 1.0 U / kg / day, of which about two thirds are prandialny (to receive food) insulin, and one third of basal insulin (base).

     Precautions : Inadequate dose or interruption of treatment, especially in insulinzavisimom diabetes (type 1) may result in giperglikemii and diabetic ketoacidosis.

Experience in clinical use in children under 6 years there. NovoRapid be used in children instead of the usual short-acting insulin only when quick action may have started better effect - for example, if the children are required to comply with the interval between injections and reception food.

Related diseases, in particular, the infection usually increase, and kidney or liver failure, reduce the need for insulin. Translation patient to a new type or brand of insulin needed to be implemented under strict medical supervision. Using drugs NovoRapid Penfill may require more injections a day or change doses, compared to those of conventional insulin preparations. If there was a need to correct dose, it could happen as early as the first introduction or in the first few weeks or months after the relocation. After compensation Carbohydrate exchange in patients can change their typical simptomy- predictor of hypoglycemia, as they should be informed. Skipping meals or unwanted physical stress can lead to hypoglycemia. With special care to apply during the drivers of vehicles and people, professions related to high concentration, because hypoglycemia can develop, especially in patients with slight or no symptoms or symptoms of hypoglycemia frequent episodes. In such cases, should seriously think about whether it is desirable for the patient to drive. Cartridge Penfill is solely for personal use. After injection for a minimum of 6 needle must remain under the skin for a full dose.

     Special instructions : Do not use the product, if the solution has ceased to be colorless and transparent.

     Shelf-life : 2.5 years

     Storage conditions : when the temperature 2-8 ° C (not freezing). Used cartridge-ranit at room temperature no higher than 30 ° C, not more than 4 weeks after the start of

Materials allowed to copy only with the active hyperlink to the handbook of medicines